Anebulo Pharmaceuticals, Inc.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals is focused on reimagining the treatment of acute cannabinoid toxicities by developing novel, best-in-class therapeutics. Their mission is to improve the lives of patients struggling with unintentional cannabis poisoning and acute cannabinoid intoxication.

Products & Services

ANEB-001:A cannabinoid antagonist designed to reverse the effects of cannabinoid intoxication, currently in development with progress through preclinical to Phase 2 stages.

Specialties

Cannabinoid intoxication treatment Development of cannabinoid antagonists Therapeutics for cannabis poisoning

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1900000 MR: - FA: up to approximately $1.9 million FAN: 1900000	D: 2024-07-22 FD: 2024-07-22	1 investors

Grant Latest

2024-07-22

$1.9M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richie Cunningham

Chief Executive Officer

K

Kenneth Cundy

Chief Scientific Officer

D

Daniel George

Acting Chief Financial Officer

J

Joseph F. Lawler

Chairman

J

Jason Aryeh

Founder and Managing General Partner of JALAA Equities, LP

N

Nat Calloway

Analyst and Partner

View 10 more team members with Pro

Unlock Full Team Directory

Recent News